The 340B program is driving up employer-sponsored health insurance premiums, according to a drug industry-funded white paper. Provider advocates criticized [...] …
Articles by : Bella Czajkowski, National Correspondent
Four drugmakers recently announced they will exempt additional states from their 340B contract pharmacy restrictions in response to a flurry [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Federal appeals court judges on Friday questioned whether four major insulin manufacturers could have imposed similar 340B contract pharmacy restrictions [...] …
The U.S. Supreme Court on Tuesday sided against more than 200 hospitals in a dispute over Medicare disproportionate share hospital [...] …
Recent Health Resources and Services Administration (HRSA) audits found that two drugmakers overcharged covered entities for their 340B drugs, fueling [...] …
The drug industry is bracing for the Trump administration’s planned tariffs on pharmaceutical products and ingredients, warning of supply chain [...] …
Minnesota covered entities will have additional 340B reporting requirements this year, but an extended deadline to submit that data, according [...] …
Tariffs on Pharmaceuticals Could Worsen Drug Shortages, Cause Disarray in 340B Prices, Advocates Say
President Donald Trump’s (R) plan to place tariffs on foreign pharmaceuticals could destabilize 340B drugs’ prices unless drugmakers absorb the [...] …
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …